JPRN-UMIN000004579招募中1 期
Phase 1/2 study of cetuximab plus capecitabine in elderly patients with kras-wild type mCRC who have no prior chemotherapy - CC with elderly kras-wild type mCRC
Department of medical oncology, Cancer institute hospital, in Japan0 个研究点目标入组 41 人开始时间: 2011年2月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 41
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 80years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Surgery or irradiation within 4weeks befor trial entry Uncontrolled comobirity Active infection unable to intake Pulmonary fibrosis, interstital pneumonia with previous medical history
研究者
相似试验
进行中（未招募）
不适用
Phase II study of cetuximab in combination with cisplatin-docetaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a biomarker-based assessment of activity. - NDon small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10001183MedDRA version: 9.1Level: LLTClassification code 10025038EUCTR2008-008387-27-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
进行中（未招募）
不适用
Randomised phase II study of cetuximab in combination with gemcitabine or gemcitabine followed by cetuximab in patients with advanced non-small-cell lung cancer, not suitable for standard platin-based therapyPatients with advanced non-small-cell lung cancer, not suitable for standard platin-based therapy.MedDRA version: 6.1Level: PTClassification code 10061873EUCTR2004-002811-98-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE100
进行中（未招募）
不适用
Phase II trial of Cetuximab in combination with chemotherapy (Carboplatinum and Navelbine) for patients with platinum-resistant head- and neckcancer - CCV-NKPlatinum-resistant head and neck cancerMedDRA version: 12.0Level: LLTClassification code 10067821Term: Head and neck cancerEUCTR2009-013878-40-DKOdense University Hospital
进行中（未招募）
1 期
Phase II study of cetuximab combined with cisplatin or carboplatin/pemetrexed as first line treatment in patients with malignant pleural mesothelioma.EUCTR2009-014293-17-BEniversity Hospital Ghent18
进行中（未招募）
不适用
Phase II study of cetuximab combined with cisplatin or carboplatin/pemetrexed as first line treatment in patients with malignant pleural mesothelioma.Patients with malignant pleural mesotheliomaMedDRA version: 13.1Level: PTClassification code 10059518Term: Pleural mesothelioma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014293-17-NLAtrium MC Parkstad18